IL307241A - Antibodies against KLRG1 - Google Patents

Antibodies against KLRG1

Info

Publication number
IL307241A
IL307241A IL307241A IL30724123A IL307241A IL 307241 A IL307241 A IL 307241A IL 307241 A IL307241 A IL 307241A IL 30724123 A IL30724123 A IL 30724123A IL 307241 A IL307241 A IL 307241A
Authority
IL
Israel
Prior art keywords
seq
antibody
antigen
cdr
binding fragment
Prior art date
Application number
IL307241A
Other languages
English (en)
Hebrew (he)
Inventor
Stefano V Gulla
Kenneth Evan Thompson
Original Assignee
Abcuro Inc
Stefano V Gulla
Kenneth Evan Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc, Stefano V Gulla, Kenneth Evan Thompson filed Critical Abcuro Inc
Publication of IL307241A publication Critical patent/IL307241A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL307241A 2021-03-26 2022-03-25 Antibodies against KLRG1 IL307241A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166663P 2021-03-26 2021-03-26
US202163294436P 2021-12-29 2021-12-29
PCT/US2022/021945 WO2022204514A1 (en) 2021-03-26 2022-03-25 Anti-klrg1 antibodies

Publications (1)

Publication Number Publication Date
IL307241A true IL307241A (en) 2023-11-01

Family

ID=81385062

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307241A IL307241A (en) 2021-03-26 2022-03-25 Antibodies against KLRG1

Country Status (10)

Country Link
US (1) US20240174754A1 (https=)
EP (1) EP4314066A1 (https=)
JP (1) JP2024515165A (https=)
KR (1) KR20230162798A (https=)
AU (1) AU2022246164A1 (https=)
BR (1) BR112023019512A2 (https=)
CA (1) CA3212311A1 (https=)
IL (1) IL307241A (https=)
MX (1) MX2023011102A (https=)
WO (1) WO2022204514A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004553A2 (pt) 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP2019518791A (ja) * 2016-06-03 2019-07-04 ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ Ｋｌｒｇ１シグナリングセラピー
WO2019169229A1 (en) * 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
BR112021004553A2 (pt) * 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1
AU2020272939A1 (en) * 2019-04-09 2021-11-11 Abcuro, Inc. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies

Also Published As

Publication number Publication date
WO2022204514A1 (en) 2022-09-29
AU2022246164A9 (en) 2024-02-22
CA3212311A1 (en) 2022-09-29
BR112023019512A2 (pt) 2023-10-31
AU2022246164A1 (en) 2023-09-28
JP2024515165A (ja) 2024-04-05
KR20230162798A (ko) 2023-11-28
MX2023011102A (es) 2023-11-28
US20240174754A1 (en) 2024-05-30
EP4314066A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
US9447182B2 (en) Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates
US12139541B2 (en) Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
IL285101B1 (en) G protein-coupled receptor-directed antibodies and methods of use
IL260402B1 (en) New psma binding antibodies and their uses
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
US20250101112A1 (en) Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
US20240174754A1 (en) Anti-klrg1 antibodies
WO2022212836A1 (en) Gpnmb antibodies and methods of use
TW202417057A (zh) 人源化的l1cam抗體藥物偶聯物
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
WO2022204529A1 (en) Anti-klrg1 antibodies
CN117321082A (zh) 抗klrg1抗体
WO2022267926A1 (zh) 一种抗tnfr2抗体及其制备方法和应用